BENEFIT Act of 2023
Official title: To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Subcommittee on Health.
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023
This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.
After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.
- Introduced in House Formatted Text PDF Formatted XML
- ALZHEIMER'S ASSOCIATION
- ALZHEIMER'S ASSOCIATION
- ALZHEIMER'S ASSOCIATION
- ALZHEIMER'S ASSOCIATION
- ALZHEIMER'S ASSOCIATION
- ALZHEIMER'S ASSOCIATION
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Centers For Disease Control & Prevention (CDC)
- Centers For Medicare and Medicaid Services (CMS)
- Federal Emergency Management Agency (FEMA)
- Food & Drug Administration (FDA)
- Government Accountability Office (GAO)
- Health & Human Services, Dept of (HHS)
Cite this page
U.S. Congress. (2026). H.R. 1092: BENEFIT Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-HR-1092/
"H.R. 1092: BENEFIT Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-1092/.
H.R. 1092, 118th Cong. (2026), https://openamerica.io/bill/118-HR-1092/.
[H.R. 1092: BENEFIT Act of 2023](https://openamerica.io/bill/118-HR-1092/)